Effects of fingolimod on focal and diffuse damage in patients with relapsing–remitting multiple sclerosis – The “EVOLUTION” study-Reference-Cited by-同舟云学术

Effects of fingolimod on focal and diffuse damage in patients with relapsing–remitting multiple sclerosis – The “EVOLUTION” study

Published:2024-07-29 Issue:9 Volume:271 Page:6181-6196
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Filippi Massimo^ORCID,Pagani Elisabetta,Turrini Renato,Bartezaghi Marta,Brescia Morra Vincenzo,Borriello Giovanna,Torri Clerici Valentina,Mirabella Massimiliano,Pasquali Livia,Patti Francesco,Totaro Rocco,Gallo Paolo,Rocca Maria A.,

Funder

Novartis Pharma

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00415-024-12590-z.pdf

Reference50 articles.

1. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S et al (2018) Multiple sclerosis. Nat Rev Dis Primers 4(1):43. https://doi.org/10.1038/s41572-018-0041-4

2. Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol 269(10):5382–5394. https://doi.org/10.1007/s00415-022-11193-w

3. Hunter SF, Bowen JD, Reder AT (2016) The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis. CNS Drugs 30(2):135–147. https://doi.org/10.1007/s40263-015-0297-0

4. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13(6):545–556. https://doi.org/10.1016/S1474-4422(14)70049-3

5. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401. https://doi.org/10.1056/NEJMoa0909494